Abivax SA Days Sales in Receivables 2023-2025 | ABVX
Current and historical days sales in receivables for Abivax SA (ABVX) from 2023 to 2025. Days sales in receivables can be defined as the average number of days it takes to collect outstanding receiveable amounts from customers. Abivax SA days sales in receivables for the three months ending March 31, 2025 was 0.00.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $6.124B | $0.000B |
| Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax SA is based in PARIS, FRANCE. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amgen (AMGN) | United States | $154.892B | 13.19 |
| CSL (CSLLY) | Australia | $67.141B | 0.00 |
| Alnylam Pharmaceuticals (ALNY) | United States | $58.528B | 0.00 |
| Alkermes (ALKS) | Ireland | $4.782B | 13.29 |
| CRISPR Therapeutics AG (CRSP) | Switzerland | $4.714B | 0.00 |
| ACADIA Pharmaceuticals (ACAD) | United States | $4.385B | 40.61 |
| ADMA Biologics Inc (ADMA) | United States | $4.119B | 29.76 |
| Ascentage Pharma Group - (AAPG) | China | $3.948B | 0.00 |
| Arcellx (ACLX) | United States | $3.848B | 0.00 |
| Akero Therapeutics (AKRO) | United States | $3.738B | 0.00 |
| Apellis Pharmaceuticals (APLS) | United States | $3.482B | 0.00 |
| Alvotech (ALVO) | Luxembourg | $2.433B | 18.34 |
| Agios Pharmaceuticals (AGIO) | United States | $2.191B | 0.00 |
| ANI Pharmaceuticals (ANIP) | United States | $2.029B | 18.19 |
| Adaptive Biotechnologies (ADPT) | United States | $2.007B | 0.00 |
| Apogee Therapeutics (APGE) | United States | $1.677B | 0.00 |
| Celldex Therapeutics (CLDX) | United States | $1.466B | 0.00 |
| Cogent Biosciences (COGT) | United States | $1.375B | 0.00 |
| AbCellera Biologics (ABCL) | Canada | $1.249B | 0.00 |
| CureVac (CVAC) | Germany | $1.205B | 5.59 |
| CorMedix Inc (CRMD) | United States | $1.107B | 19.77 |
| Arbutus Biopharma (ABUS) | United States | $0.711B | 0.00 |
| Castle Biosciences (CSTL) | United States | $0.696B | 68.60 |
| AnaptysBio (ANAB) | United States | $0.569B | 0.00 |
| Cytek Biosciences (CTKB) | United States | $0.527B | 0.00 |
| Alumis (ALMS) | United States | $0.483B | 0.00 |
| Compass Therapeutics (CMPX) | United States | $0.483B | 0.00 |
| Corvus Pharmaceuticals (CRVS) | United States | $0.428B | 0.00 |
| Absci (ABSI) | United States | $0.357B | 0.00 |
| Abeona Therapeutics (ABEO) | United States | $0.350B | 7.42 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.345B | 0.00 |
| CytomX Therapeutics (CTMX) | United States | $0.336B | 3.64 |
| Amarin (AMRN) | Ireland | $0.311B | 0.00 |
| Contineum Therapeutics (CTNM) | United States | $0.293B | 0.00 |
| Allogene Therapeutics (ALLO) | United States | $0.251B | 0.00 |
| Alector (ALEC) | United States | $0.238B | 0.00 |
| Annexon (ANNX) | United States | $0.226B | 0.00 |
| Adocia (ADOCY) | France | $0.216B | 0.00 |
| AC Immune (ACIU) | Switzerland | $0.205B | 0.00 |
| Aardvark Therapeutics (AARD) | United States | $0.180B | 0.00 |
| Actuate Therapeutics (ACTU) | United States | $0.175B | 0.00 |
| Caribou Biosciences (CRBU) | United States | $0.174B | 0.00 |
| Citius Oncology (CTOR) | United States | $0.170B | 0.00 |
| Climb Bio (CLYM) | United States | $0.151B | 0.00 |
| Cellectis S.A (CLLS) | France | $0.143B | 0.00 |
| Cardiff Oncology (CRDF) | United States | $0.140B | 0.00 |
| Anika Therapeutics (ANIK) | United States | $0.135B | 0.00 |
| Coherus Oncology (CHRS) | United States | $0.135B | 0.00 |
| Alpha Cognition (ACOG) | Canada | $0.134B | 0.00 |
| Agenus (AGEN) | United States | $0.133B | 0.00 |
| Connect Biopharma Holdings (CNTB) | United States | $0.115B | 0.00 |
| Coya Therapeutics (COYA) | United States | $0.110B | 0.00 |
| Anebulo Pharmaceuticals (ANEB) | United States | $0.103B | 0.00 |
| Adagene (ADAG) | China | $0.100B | 0.00 |
| Alto Neuroscience (ANRO) | United States | $0.100B | 0.00 |
| ANIXA BIOSCIENCES INC (ANIX) | United States | $0.096B | 0.00 |
| CervoMed (CRVO) | United States | $0.089B | 0.00 |
| Acumen Pharmaceuticals (ABOS) | United States | $0.082B | 0.00 |
| Applied Therapeutics (APLT) | United States | $0.071B | 0.00 |
| ABVC BioPharma (ABVC) | United States | $0.067B | 0.00 |
| Aligos Therapeutics (ALGS) | United States | $0.065B | 0.00 |
| Adverum Biotechnologies (ADVM) | United States | $0.065B | 0.00 |
| Coeptis Therapeutics Holdings (COEP) | United States | $0.064B | 0.00 |
| ALX Oncology Holdings (ALXO) | United States | $0.063B | 0.00 |
| Adlai Nortye (ANL) | Cayman Islands | $0.062B | 0.00 |
| Cue Biopharma (CUE) | United States | $0.060B | 0.00 |
| Adicet Bio (ACET) | United States | $0.060B | 0.00 |
| Clene (CLNN) | United States | $0.053B | 0.00 |
| Annovis Bio (ANVS) | United States | $0.045B | 0.00 |
| CollPlant Biotechnologies (CLGN) | Israel | $0.033B | 0.00 |
| AN2 Therapeutics (ANTX) | United States | $0.030B | 0.00 |
| Clearside Biomedical (CLSD) | United States | $0.029B | 0.00 |
| Cadrenal Therapeutics (CVKD) | United States | $0.027B | 0.00 |
| Akari Therapeutics (AKTX) | United Kingdom | $0.024B | 0.00 |
| Allarity Therapeutics (ALLR) | United States | $0.023B | 0.00 |
| Cingulate (CING) | United States | $0.022B | 0.00 |
| Curis (CRIS) | United States | $0.021B | 0.00 |
| Abpro Holdings (ABP) | United States | $0.020B | 0.00 |
| Cuprina Holdings (Cayman) (CUPR) | Singapore | $0.019B | 0.00 |
| Adaptimmune Therapeutics (ADAP) | United Kingdom | $0.016B | 0.00 |
| Cocrystal Pharma (COCP) | United States | $0.015B | 0.00 |
| Chemomab Therapeutics (CMMB) | Israel | $0.015B | 0.00 |
| COSCIENS Biopharma (CSCI) | Canada | $0.010B | 0.00 |
| Advanced Biomed (ADVB) | United States | $0.009B | 0.00 |
| Adial Pharmaceuticals (ADIL) | United States | $0.008B | 0.00 |
| Avalon GloboCare (ALBT) | United States | $0.008B | 0.00 |
| Acurx Pharmaceuticals (ACXP) | United States | $0.007B | 0.00 |
| Alzamend Neuro (ALZN) | United States | $0.007B | 0.00 |
| Apollomics (APLM) | United States | $0.004B | 0.00 |
| CNS Pharmaceuticals (CNSP) | United States | $0.004B | 0.00 |
| Aceragen (ACGN) | United States | $0.000B | 0.00 |
| Clovis Oncology (CLVSQ) | United States | $0.000B | 0.00 |